Fabio
91 lines
5.1 KiB
Markdown
91 lines
5.1 KiB
Markdown
---
|
||
type: "Bill"
|
||
title: "Pharmaceutical Substance Manufacturing Grant Fund; created."
|
||
description: "Pharmaceutical Substance Manufacturing Grant Fund. Establishes the Pharmaceutical Substance Manufacturing Grant Fund to provide grant installment awards between July 1, 2026, and July 1, 2045, in an amount not to exceed $34 million per fiscal year and in an aggregate amount not to exceed $191,255,000, to a qualified company that (i) engages in the manufacture of pharmaceutical substances, (ii) executes a memorandum of understanding with the Commonwealth, and (iii) is expected to make a capital investment of at least $4 billion and create and maintain at least 500 new full-time jobs. This bill is identical to SB 527."
|
||
jurisdiction: "us/states/va"
|
||
legislature: "Virginia General Assembly"
|
||
session: "2026"
|
||
identifier: "HB 1076"
|
||
citation: "Virginia HB 1076 (2026)"
|
||
classification: ["bill"]
|
||
subjects: []
|
||
status: "enacted"
|
||
primary_sponsors: ["Amy J. Laufer"]
|
||
version_count: 2
|
||
action_count: 27
|
||
vote_count: 6
|
||
first_action: "2026-01-14"
|
||
last_action: "2026-04-13"
|
||
source: "openstates"
|
||
source_identifier: "ocd-bill/a64e4dbc-7307-4e92-aa49-2f1738a9cf47"
|
||
source_url: "https://lis.virginia.gov/bill-details/20261/HB1076"
|
||
source_hash: "387ef277c3b1cc584035850ecd9fa5f964f09f0637cc622e902375c9ec1e9812"
|
||
vintage: "2026-07-01"
|
||
source_snapshot: "https://data.openstates.org/daily/2026-07-01/public.pgdump"
|
||
retrieved_at: "2026-07-06"
|
||
confidence: "reported"
|
||
tags: ["legislation", "bill", "us-va"]
|
||
---
|
||
|
||
# Virginia HB 1076 (2026) — Pharmaceutical Substance Manufacturing Grant Fund; created.
|
||
|
||
Pharmaceutical Substance Manufacturing Grant Fund. Establishes the Pharmaceutical Substance Manufacturing Grant Fund to provide grant installment awards between July 1, 2026, and July 1, 2045, in an amount not to exceed $34 million per fiscal year and in an aggregate amount not to exceed $191,255,000, to a qualified company that (i) engages in the manufacture of pharmaceutical substances, (ii) executes a memorandum of understanding with the Commonwealth, and (iii) is expected to make a capital investment of at least $4 billion and create and maintain at least 500 new full-time jobs. This bill is identical to SB 527.
|
||
|
||
## Version chain
|
||
|
||
The bill's text revisions, in order — the diff chain from filing to enrollment.
|
||
|
||
1. **Introduced** (filed) — [source](https://lis.blob.core.windows.net/files/1087325.PDF)
|
||
2. **Enrolled** (enrolled) — [source](https://lis.blob.core.windows.net/files/1171574.PDF)
|
||
|
||
## Votes
|
||
|
||
- Reported from Appropriations — **21–0** (pass) · lower
|
||
- Reported from Finance and Appropriations — **13–0** (pass) · upper
|
||
- H VOTE: — **92–5** (pass) · lower
|
||
- Passage R — **39–0** (pass) · upper
|
||
- Constitutional reading dispensed (on 2nd reading) — **38–0** (pass) · upper
|
||
- Subcommittee recommends reporting — **5–0** (pass) · lower
|
||
|
||
## Sponsors
|
||
|
||
- Amy J. Laufer — primary (person)
|
||
- Katrina Callsen — cosponsor (person)
|
||
|
||
## Timeline
|
||
|
||
The legislative action history — every referral, reading, and vote.
|
||
|
||
- **2026-01-14** Prefiled and ordered printed; Offered 01-14-2026 26102903D `filing, introduction`
|
||
- **2026-01-14** Referred to Committee on Appropriations `referral-committee`
|
||
- **2026-01-22** Assigned HAPP sub: Commerce Agriculture & Natural Resources `referral-committee`
|
||
- **2026-01-23** Fiscal Impact Statement from Department of Planning and Budget (HB1076)
|
||
- **2026-01-28** Subcommittee recommends reporting (5-Y 0-N)
|
||
- **2026-01-30** Reported from Appropriations (21-Y 0-N) `committee-passage`
|
||
- **2026-02-03** Read first time `reading-1`
|
||
- **2026-02-04** Moved from Uncontested Calendar to Regular Calendar
|
||
- **2026-02-04** Read second time and engrossed `reading-2`
|
||
- **2026-02-05** Read third time and passed House (92-Y 5-N 0-A) `passage, reading-3`
|
||
- **2026-02-06** Constitutional reading dispensed (on 1st reading)
|
||
- **2026-02-06** Referred to Committee on Finance and Appropriations `referral-committee`
|
||
- **2026-02-17** Reported from Finance and Appropriations (13-Y 0-N) `committee-passage`
|
||
- **2026-02-18** Read second time `reading-2`
|
||
- **2026-02-18** Rules suspended
|
||
- **2026-02-18** Constitutional reading dispensed Block Vote (on 2nd reading) (38-Y 0-N 0-A)
|
||
- **2026-02-18** Passed by for the day
|
||
- **2026-02-19** Read third time `reading-3`
|
||
- **2026-02-19** Passed Senate Block Vote (39-Y 0-N 0-A) `passage`
|
||
- **2026-02-23** Enrolled `enrolled`
|
||
- **2026-02-23** Bill text as passed House and Senate (HB1076ER) `passage`
|
||
- **2026-02-23** Fiscal Impact Statement from Department of Planning and Budget (HB1076)
|
||
- **2026-02-23** Signed by Speaker `passage`
|
||
- **2026-02-23** Signed by President `passage`
|
||
- **2026-03-10** Enrolled Bill communicated to Governor on March 10, 2026 `enrolled, executive-receipt`
|
||
- **2026-03-10** Governor's Action Deadline 11:59 p.m., April 13, 2026 `executive-receipt`
|
||
- **2026-04-13** Approved by Governor-Chapter 808 (effective 7/1/2026) `executive-signature`
|
||
|
||
## Source
|
||
|
||
OpenStates / OpenCivicData bulk snapshot [2026-07-01](https://data.openstates.org/daily/2026-07-01/public.pgdump); origin `ocd-bill/a64e4dbc-7307-4e92-aa49-2f1738a9cf47`. Confidence: reported (aggregated from official Virginia legislature records).
|
||
|